IL-1β +3954C>T — A Silent Mutation That Amplifies Inflammation
Interleukin-1 beta (IL-1β) is one of the most potent pro-inflammatory cytokines in
the human immune system | IL-1β activates NF-κB signaling, drives fever, induces acute
phase proteins, promotes neutrophil recruitment, and directly stimulates bone resorption
— all fundamental to both protective immunity and inflammatory disease.
The IL1B gene encodes this cytokine on chromosome 2, and the rs1143634 variant at
exon 5 position +3954 presents an unusual biological puzzle: a synonymous mutation
— one that preserves the amino acid sequence — that nonetheless changes how much
IL-1β protein the body produces | The F105F substitution (Phe→Phe) is silent at the
protein level but functionally loud at the secretion level.
The Mechanism
The +3954C>T variant (rs1143634) is located in exon 5 of IL1B, in the region
encoding the mature IL-1β protein's domain critical for receptor binding. Despite
causing no amino acid change at position 105 (phenylalanine is retained regardless of
C or T), carriers of the T allele produce substantially more IL-1β protein after
immune stimulation | In a study of aseptic implant loosening, T allele carriers had
plasma IL-1β levels of 11.79 pg/mL versus 2.11 pg/mL in CC homozygotes after
stimulation — a 5.6-fold difference.
The mechanism by which a synonymous codon change alters protein secretion likely
operates at the post-transcriptional level. Synonymous variants can alter mRNA
secondary structure, codon usage optimization, or regulatory element binding within
the coding sequence | These effects can influence mRNA stability, translation
efficiency, or protein folding — and for IL-1β, which requires caspase-1 cleavage
for secretion, subtle conformational changes in the precursor protein could plausibly
accelerate or facilitate the secretion process.
In vitro studies show that the T allele leads to measurably higher IL-1β release from
lipopolysaccharide-stimulated immune cells compared to the C allele.
This variant is distinct from the better-known promoter variants in IL1B: rs16944
(-511C>T) and rs1143627 (-31T>C) | These two promoter variants regulate IL-1β
transcription; rs1143634 instead appears to affect post-translational secretion
or processing, providing an independent second tier of IL-1β output control.
A person who carries high-producing alleles at multiple IL1B loci may have compounded
elevation of IL-1β output.
The Evidence
The strongest and most consistent evidence links rs1143634 to periodontal disease.
A meta-analysis of 54 case-control studies encompassing 9,376 participants |
Association between the rs1143634 polymorphism in interleukin-1B and chronic
periodontitis. Journal of Periodontal Research, 2018
found the T allele significantly associated with chronic periodontitis risk
(OR 1.35, 95% CI 1.24–1.48; p < 0.00001). Stratified analyses confirmed the
association in Caucasian, Asian, and mixed populations, though not in African
ancestry cohorts.
The aseptic joint loosening study | IL-1β gene (+3954C/T) and NOS2 polymorphisms
associate with early aseptic loosening of arthroplasties. Scientific Reports,
2022 provided some of the most
compelling functional evidence: patients with the TT genotype showed a 3.7-fold
higher hazard of requiring revision surgery within 5 years (HR 3.70, 95% CI
1.27–10.75), with the elevated IL-1β levels directly driving peri-implant bone
resorption. This study confirmed the secretion phenotype rather than just disease
association.
For cancer risk, an updated meta-analysis of 44 studies (18,645 cancer patients,
22,882 controls) | Role of IL-1β rs1143634 (+3954C>T) polymorphism in cancer risk.
International Journal of General Medicine, 2021
found the T allele associated with modestly elevated overall cancer risk
(allelic model OR 1.08). Gastric cancer, breast cancer, and multiple myeloma
showed the most consistent signals in subgroup analyses.
In inflammatory bowel disease, IL1B gene polymorphisms including the exon 5 variant
were shown to influence the course and severity of IBD in a study of 96 UC and
98 Crohn's patients | IL1B gene polymorphisms influence the course and severity
of inflammatory bowel disease. Gut, 2000,
establishing a role for this variant in gastrointestinal inflammatory disease
progression rather than susceptibility alone.
A notable negative finding: the T allele is not associated with aggressive
periodontitis (OR 0.99, 95% CI 0.79–1.23 in a 25-study meta-analysis) — the
association is specific to chronic periodontitis. This distinction matters clinically:
aggressive and chronic periodontitis have different etiologies and risk profiles,
and the IL-1β elevation associated with this variant appears to drive the
sustained chronic inflammatory pattern rather than acute-onset aggressive disease.
Practical Actions
Elevated IL-1β production from this variant is not inevitably harmful — it is a
quantitative trait that becomes clinically relevant under specific conditions.
The most actionable implications:
Dental health: Carriers of one or two T alleles have meaningfully elevated
periodontal risk. The T allele is particularly dangerous in combination with smoking,
where the risk amplifies substantially. The variant provides a genetic basis for
prioritizing periodontal care beyond standard recommendations.
Inflammatory conditions: Elevated baseline IL-1β production may accelerate
inflammation-driven tissue damage in contexts ranging from joint prostheses to
gastrointestinal mucosa. Conditions where IL-1β is a known mediator — including
gout, IBD flares, and peri-implant inflammation — may be more severe in T allele
carriers.
Cancer context: The modest cancer risk elevation (OR ~1.08) is not sufficient
to change standard screening protocols, but it reinforces the importance of
anti-inflammatory strategies and standard cancer screening adherence.
Interactions
rs1143634 is part of the IL1B locus on chromosome 2q14.1, which also encodes
IL1A, and is co-located with the IL1RN gene encoding the IL-1 receptor antagonist.
The promoter variants rs16944 (−511) and rs1143627 (−31) regulate IL-1β transcription
via different mechanisms from rs1143634. A person carrying risk alleles at both the
promoter level (rs16944) and the exon 5 level (rs1143634) may have compounded
IL-1β output — both more transcript and more efficient secretion of the protein.
Interaction with IL1RN rs419598 (the IL-1 receptor antagonist gene) is biologically
important: IL-1Ra counterbalances IL-1β by competing for the IL-1 receptor without
signaling. Carrying the rs1143634 T allele (high IL-1β) alongside low-producing IL-1Ra
variants may amplify net IL-1 signaling substantially.
The composite IL-1 genotype combining IL1A rs1800587 and IL1B rs1143634 was shown
to have a 2.84-fold risk of chronic periodontitis in smokers (OR 4.43 in male smokers,
OR 6.00 in female smokers) | Interaction of IL1B and IL1RN polymorphisms, smoking,
gender and ethnicity with aggressive and chronic periodontitis susceptibility.
J Clin Periodontol, 2016, illustrating
that single-variant effects are substantially potentiated in this combined context.
Alla genotyper
Standard IL-1β secretion — common wild-type genotype
You carry two copies of the G allele (corresponding to the C allele in the coding-strand notation used in many papers about this variant). This is the most common genotype, found in approximately 61% of people globally and about 58% of Europeans. Your IL-1β secretion from immune cells falls within the typical range for this variant — without the secretion-amplifying effect of the T/A allele at position 105 of the protein.
One T allele — moderately elevated IL-1β secretion capacity
You carry one A allele (the T allele in coding-strand notation), which increases IL-1β protein secretion from your immune cells compared to GG homozygotes. About 34% of people globally share this genotype; in Europeans it is approximately 36%. Research links one copy of this allele to moderately elevated risk of chronic periodontitis (OR ~1.35 in large meta-analyses) and modest increases in overall inflammatory disease susceptibility.
Two T alleles — substantially elevated IL-1β secretion and inflammatory risk
You carry two copies of the A allele (TT in coding-strand notation), the genotype most strongly associated with elevated IL-1β protein secretion. About 5% of people globally, and roughly 6% of Europeans, share this genotype. Studies directly measuring plasma IL-1β levels found TT carriers produce approximately 5.6 times more IL-1β than CC carriers after immune stimulation (11.79 vs 2.11 pg/mL). This elevated cytokine tone increases your risk for chronic periodontitis, peri-implant inflammation, and may modestly amplify susceptibility to other IL-1β-driven inflammatory conditions.